and ␤. They include three different receptors that regulate gene expression in response to thyroid hormone (TR␣1, TR␤1, and TR␤2) and two variant molecules (TR␣2, TR␣3) that do not bind thyroid hormone but are likely to modify the actions of the true receptors.
Each TR has a characteristic tissue expression. TR␤1 is expressed widely and at high levels in liver and kidney; TR␤2 is particularly abundant in the pituitary and hypothalamus; and TR␣1 is rather ubiquitous with high levels in the heart (9) . This pattern of expression is likely to explain why patients with mutant TR␤ alleles have abnormal regulation of thyroid stimulating hormone in the pituitary, resulting in elevated serum-free thyroid hormone levels (10) . Organs with high levels of TR␤ relative to TR␣, such as the liver, display evidence of tissue hypothyroidism. On the other hand, the cardiac function of patients with TR␤ mutations is often suggestive of hyperthyroidism. This is thought to be due to the predominance of TR␣ in this organ. Experimental studies in mice support the concept that TR␤ predominates in pituitary and liver, whereas TR␣ is the major thyroid receptor in the heart. Mice lacking TR␤ have elevated TSH, elevated thyroid hormone levels, and hepatic abnormalities consistent with hypothyroidism (11) . By contrast, mice lacking TR␣ have a quite different phenotype, with evidence of cardiac hypothyroidism (12) .
At the molecular level, TR␤1 and TR␤2 have identical C-terminal ligand binding domains (LBDs), suggesting that it will be difficult to develop molecules that differentially interact with or regulate the activity of these two TRs, which from this point on will be referred to collectively as TR␤. TR␣ and TR␤ have very similar C-terminal LBDs, but enough differences that it is reasonable to imagine the development of small molecules that distinguish TR␣ from TR␤. One such candidate is a recently described TR␤-specific high-affinity agonist, GC-1 (13) . In this issue of Endocrinology, Trost et al. show that GC-1 was equally or more effective than T 3 in lowering cholesterol and triglycerides, presumably due to its actions on TR␤ in liver (14) . It also potently decreased TSH levels, probably via TR␤2 in pituitary (15) . However, GC-1 was a less potent regulator of thyroid hormone action in the heart as assessed by physiological parameters of heart rate and inotropy as well as by molecular analysis of thyroidresponsive genes. These results are consistent with a relative sparing of TR␣ by this thyromimetic compound in vivo. Of note, the authors also found that GC-1 preferentially accumulated in the liver, suggesting a second mechanism of tissue selectivity that is probably unrelated to the TR␤ selectivity of this compound. Nevertheless, the beneficial effects of GC-1 without overt cardiac toxicity support the authors' optimism about the potential to use receptor-and/or tissue-selective thyromimetic compounds to treat diseases other than hypothyroidism.
When bound by natural thyroid hormones such as T 3 , TR␣ and TR␤ both assume conformations that display increased affinity for molecules called coactivators, which communicate a positive signal to the transcriptional machinery leading to gene activation (16) . Interactions between TR and opposing coregulators, called corepressors, are reciprocally destabilized by binding of T 3 (17) . It is not yet known whether the GC-1 bound TR␤ interacts with the same range of coactivators as the TR bound to T 3 or, for that matter, whether GC-1 binding causes corepressor to dissociate from TR. Specificity at the level of coregulator recruitment could be a determinant of unique properties of GC-1 or, possibly, future tissuespecific thyromimetics. Indeed, is now recognized that selective estrogen receptor modulators work in part by inducing a ligand-bound conformation that facilitates corepressor but not coactivator binding to the estrogen receptor (18, 19) .
GC-1 is an example of a thyromimetic whose tissue specificity is at least in part due to differential binding to TR␣ and TR␤. The search for additional receptor-specific compounds will be aided not only by using GC-1 as a lead, but by taking advantage of rapidly emerging structural information. The three-dimensional structure of ligand-bound TR␣ LBD is already available (20) , and it seems a certainty that the structures of liganded TR␤ and the unliganded TRs will be forthcoming. Comparison of the structures of T 3 -bound TR␣ and TR␤ with that of GC-1-occupied TR␤ will be particularly useful in determining the basis of TR␣ vs. TR␤ selectivity at the atomic level.
It may also be possible for chemists to create molecules that distinguish between TR␣ and TR␤ not at the level of binding affinity but, rather, by the complement of coactivators and corepressors that are recruited to the ligand-bound TRs. Structural information about the role of ligand in creating or stabilizing the coregulator binding site should be a useful guide to the development of such compounds (21) . It will then be the role of biologists to empirically determine whether novel combinations of thyromimetic receptor binding and coregulator recruitment can be correlated with a desired pharmacological effect, and whether this can be dissociated from the toxicities associated with high levels of thyroid hormone. Now that we have a sense of the underlying complexity and multiplicity of thyroid hormone receptors and their coregulators, it seems likely that promising new therapeutics could emerge from this line of investigation. 
